Clinical application of oxintuzumab/oxintuzumab (Besponsa)

Besponsa (, B-ALL). B-ALL is a rare but serious type of leukemia that usually occurs in adults, especially those who have become resistant to or relapsed with traditional treatments. Oplusintuzumab/The introduction of intuzumab provides a new treatment option for these patients.

The main mechanism of action of oxinutuzumab/oxinutuzumab is to interfere with the growth and survival of leukemia cells by targeting the CD22 antigen on the surface of lymphocytes. CD22is a protein that sits on the surface of B cells, and in B-ALL patients, the leukemia cells often express CD22. Ogaintozumab/Ointozumab binds to CD22 antigen, preventing the normal function of leukemia cells, thereby reducing their number, and helps treat acute lymphoblastic leukemia.

In clinical application, oxinutuzumab/oxinutuzumab is usually administered by intravenous injection, and the treatment cycle may vary according to the specific conditions of the patient. Patients need to be closely supervised by their doctors during treatment to ensure the effectiveness and safety of the treatment, and undergo regular examinations and monitoring during the treatment process.

The clinical application of oxinutuzumab/oxinutuzumab represents an important advance in the treatment of leukemia. It isB-ALLIt provides patients with an innovative, targeted treatment option that is expected to improve patients' survival rates and quality of life. However, patients should consult a physician before receiving treatment to develop a personalized treatment plan and communicate with the medical team regularly during treatment to ensure optimal treatment results.

Ogaintozumab/Ointozumab has been launched in China, but it is not included in medical insurance. The domestic price is around 60,000 to 70,000 yuan, which is very expensive. Patients can buy it domestically. There are only original drugs available abroad, mainly Pfizer’s original drugs, which cost more than 80,000 yuan.